Analysis of the efficacy of poly ADP-ribose polymerases inhibitor combined with chemotherapeutics in the treatment of triple negative breast cancer

Objective To investigate the effects of poly adenosine diphosphate ribose polymerase (PARP) inhibitor AG014699 on the proliferation of triple negative breast cancer (TNBC) cell line MDA-MB-231. Methods Cell proliferation and cytotoxicity test kit (CCK-8) was used to detect the proliferation of MDA-MB-231 cells in different concentrations of AG014699 (0.1, 1.0, 10.0, 20.0 and 40.0 mmol/L), DTX (10-9, 10-8, 10-7, 10-6 and 10-5 mol/L) and CBP (10-6, 10-5, 10-4 and 10-3 mol/L). Flow cytometry was used to detect cell apoptosis and cell cycle distribution. Results The effects of AG01469 at different concentrations (0.1, 1.0, 10.0, 20.0 and 40.0 μmol/L) on proliferation activity of MDA-MB-231 cells were(94.83±3.93)%, (79.42±5.52)%, (63.75±4.34)%, (38.97±8.42)%, (29.70±3.35)%, with statistically significant differences (F=75.54, P 0.05 at 10-9 concentration and P 0.05 at 10-6 concentration, P 1.15 when AG014699 was combined with 10-3 mmol/L CBP, which showed synergistic effect.When combined with other effective concentrations of DTX or CBP, the q value was between 0.85 and 1.15, showing additive effect. Conclusion PARP inhibitor AG014699 assisted DTX or CBP can inhibit the proliferation of TNBC cell line MDA-MB-231.By means of simple addition or systematic effect, it can inhibit the triple negative breast cancer. Key words: Triple negative breast cancer; Poly adenosine diphosphate ribose polymerase; Docetaxel; Carboplatin